Adipose-derived mesenchymal stromal cell-derived exosomes promote tendon healing by activating both SMAD1/5/9 and SMAD2/3

Hengchen Liu†, Mingzhao Zhang†, Manyu Shi†, Tingting Zhang, Wenjun Lu, Shulong Yang, Qingbo Cui* and Zhaozhu Li*

Abstract

Background: The use of adipose-derived mesenchymal stromal cell-derived exosomes (ADSC-Exos) may become a new therapeutic method in biomedicine owing to their important role in regenerative medicine. However, the role of ADSC-Exos in tendon repair has not yet been evaluated. Therefore, we aimed to clarify the healing effects of ADSC-Exos on tendon injury.

Methods: The adipose-derived mesenchymal stromal cells (ADSCs) and tendon stem cells (TSCs) were isolated from the subcutaneous fat and tendon tissues of Sprague-Dawley rats, respectively, and exosomes were isolated from ADSCs. The proliferation and migration of TSCs induced by ADSC-Exos were analyzed by EdU, cell scratch, and transwell assays. We used western blot to analyze the tenogenic differentiation of TSCs and the role of the SMAD signaling pathways. Then, we explored a new treatment method for tendon injury, combining exosome therapy with local targeting using a biohydrogel. Immunofluorescence and immunohistochemistry were used to detect the expression of inflammatory and tenogenic differentiation after tendon injury, respectively. The quality of tendon healing was evaluated by hematoxylin-eosin (H&E) staining and biomechanical testing.

Results: ADSC-Exos could be absorbed by TSCs and promoted the proliferation, migration, and tenogenic differentiation of these cells. This effect may have depended on the activation of the SMAD2/3 and SMAD1/5/9 pathways. Furthermore, ADSC-Exos inhibited the early inflammatory reaction and promoted tendon healing in vivo.

Conclusions: Overall, we demonstrated that ADSC-Exos contributed to tendon regeneration and provided proof of concept of a new approach for treating tendon injuries.

Keywords: Mesenchymal stromal cells, Tendon stem cells, Exosomes, SMAD, Tendon healing
**Introduction**

Tendon is a dense connective tissue consisting of limited tendon cells and abundant extracellular matrix (ECM). Tendon injuries are of significant concern worldwide, with more than 30 million affected patients annually [1]. Tendon healing is slow as a result of its hypocellularity and hypovascularity and involves three overlapping phases: inflammation, proliferation, and remodeling [2, 3]. Furthermore, the self-healing potential of any tissue depends, in part, on its endogenous resident stem cells. The viability and tenogenic differentiation of tendon stem cells (TSCs) are the main mechanisms of tendon repair [4]. However, inflammation during the healing phase may compromise biomechanical function [5–7]. Therefore, it is important to enhance tendon healing by promoting anti-inflammation and the proliferation of TSCs.

Mesenchymal stromal cells have demonstrated great potential in tissue healing [8]. Specifically, adipose-derived mesenchymal stromal cells (ADSCs) are highly beneficial for clinical applications because of their abundant and conveniently accessible sources [9]. When transplanted, ADSCs are able to modulate the inflammatory environment and abundant extracellular matrix (ECM) balance to stimulate tendon regeneration [10–12]. Recent studies have demonstrated that the effectiveness of ADSCs in regenerative medicine is due to their paracrine effects [13]. Thus, ADSCs have been identified as new therapeutic agents in biomedicine [14].

Exosomes are membrane-bound extracellular vesicles that target cells by endocytosis, membrane fusion, or receptor-ligand interaction and are important paracrine factors for stromal cells [15]. In addition, exosomes play important roles in immune regulation, apoptosis, and tissue regeneration [16]. The therapeutic effect of ADSC-Exos has been demonstrated in multiple diseases. This is of great significance in the future development of tissue repair and regeneration engineering [17].

We hypothesize that ADSC-Exos promote tendon repair by regulating the biological characteristics of TSCs as well as the extracellular microenvironment. Specifically, in this study, we investigated the effects of ADSC-Exos on the proliferation, migration, and differentiation of TSCs in vitro, and during inflammation and regeneration situations in vivo.

**Materials and methods**

**Animals**

Male Sprague-Dawley rats weighing 180–230 g at 8–10 weeks of age were provided by the Experiment Center of Harbin Medical University (Harbin, Heilongjiang, China). All animals were treated according to the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the protocol was approved by the corresponding ethics committee (no. Ky2018-135).

**Isolation and identification of TSCs and ADSCs**

The isolation methods of ADSCs and TSCs were performed as in previous studies [18, 19]. In brief, TSCs were isolated from rat tendon and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS) (Biological Industries, Kibbutz Beit-Haemek, Israel) and 1% penicillin-streptomycin (Beyotime, Hai men, China). The multilineage differentiation potential of TSCs, as well as the identification of surface markers (CD90- and CD105-positive; CD106- and CD11b-negative), was demonstrated in our previous study [19]. ADSCs were isolated from the subcutaneous fat of rats and cultured in DMEM/F12 (Invitrogen) containing 10% FBS and 1% penicillin-streptomycin. Flow cytometry was used to identify surface markers. The adipogenic, osteogenic, and chondrogenic differentiation of ADSCs was induced in a differentiation medium (Cyagen, Santa Clara, CA, USA) to identify their differentiation potential.

**Isolation and identification of ADSC-Exos**

At 80% confluence, the culture medium of the ADSCs was changed to exosome-depleted medium (DMEM/F12 containing 10% exosome-depleted FBS (Biological Industries) and 1% penicillin-streptomycin) and incubated for 24 h. Then, the culture medium was collected without ADSCs and centrifuged at 300×g for 10 min, 3000×g for 10 min, 10,000×g for 30 min, and 100,000×g for 2 h to isolate the exosomes. Exosomes attached to the bottom of the centrifuge tube were diluted with phosphate-buffered saline. Nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and western blotting were used to identify and evaluate the collected exosomes.

**Cellular internalization of ADSC-Exos**

ADSC-Exos were incubated with 1 μM PKH26 (Sigma-Aldrich, St. Louis, MO, USA) in Diluent C (Sigma-Aldrich) for 5 min, and excess dye was removed by ultracentrifugation. The labeled exosomes were subsequently added to the serum-free medium of TSC cultures and incubated overnight. The nuclei were labeled with Hoechst 33342 (UE, China), and photos were taken with an inverted fluorescence microscope (Leica, Wetzlar, Germany).

**ADSC-Exo release analysis**

The ADSC-Exo release analysis was performed using the BCA protein assay kit (Beyotime, China) as previously described [20]. Briefly, gelatin methacryloyl (GelMA)
loaded with 200 μg ADSC-Exos was immersed in PBS in a 24-well plate. The supernatant was collected every 24 h for determining ADSC-Exo release, and new PBS was added. The released ADSC-Exos were quantified and expressed as the release percentage.

**Treatment of TSCs with ADSC-Exos**
First, to determine the effect of ADSC-Exo treatment on TSCs, 1 × 10⁶ TSCs were seeded into six-well culture plates for 24 h and divided randomly into four groups. ADSC-Exos were added to the exosome-free medium at 0, 25, 50, or 100 μg/mL and used to replace the TSC culture medium. Next, to further study the related mechanisms, we randomly sorted TSCs seeded in six-well culture plates into four groups as follows: (1) control: exosome-free medium was used to replace the TSC culture medium; (2) ADSC-Exos: 50 μg/mL ADSC-Exos was added to the exosome-free medium and used to replace the TSC culture medium; (3) ADSC-Exos+SB: 10 nM of the SMAD2/3 inhibitor SB431542 (MedChemExpress, Monmouth Junction, NJ, USA) was added to the TSCs 30 min before the addition of 50 μg/mL ADSC-Exos and (4) ADSC-Exos+DM: 10 nM of the SMAD1/5/9 inhibitor dorsomorphin (MedChemExpress) was added to the TSCs 30 min before addition of 50 μg/mL ADSC-Exos. TSCs from all the experimental groups were collected after 30 min or 24 h for western blotting. In addition, EdU, scratch, and transwell assays were performed after 24 h.

**EdU assay**
For the cell proliferation analysis, TSCs were incubated with 50 μM 5-ethynyl-2′-deoxyuridine (EdU) from an EdU Assay Kit (UE) for 4 h. The TSCs were then fixed with 4% paraformaldehyde and stained using the same EdU assay kit. The nuclei were labeled with Hoechst 33342, and photos were taken with an inverted fluorescence microscope.

**Scratch assay**
TSCs at 2 × 10⁵ cells/well were inoculated into a 6-well plate for overnight culture. A straight-line wound was made in the cultured cells using a sterile 200-μL pipette tip. A serum-free medium with ADSC-Exos was then added into each well. Images were obtained at 0 and 24 h after ADSC-Exo treatment using an inverted microscope with an Axiocam 506 camera and ZEN 2011 software (Zeiss, Oberkochen, Germany).

**Transwell assay**
TSCs at 1 × 10⁵ cells/well were inoculated into the transwell upper chamber, and ADSC-Exos were added into the lower compartment. After culturing for 24 h, the TSCs were fixed with absolute ethanol, then stained with crystal violet. Images were obtained under a light microscope.

**Western blot analyses**
TSCs were lysed in radioimmunoprecipitation assay buffer (Beyotime). Immunoblotting was performed using the following rabbit primary antibodies: anti-CD9 (monoclonal; 1:2000; ab92726; Abcam, Cambridge, UK), abti-TSG101 (monoclonal; 1:2000; ab125011; Abcam), anti-Hsp70 (monoclonal; 1:1000; ab2787; Abcam), anti-tenomodulin (anti-TNMD; polyclonal; 1:1000; ab203676; Abcam), anti-collagen I (monoclonal; 1:1000; ab270993; Abcam), anti-scleraxis (anti-SCXA; polyclonal; 1:500; DF13293; Affinity Biologicals, Ancaster, ON, Canada), anti-alkaline phosphatase (anti-ALP; polyclonal; 1:1000; DF6225; Affinity Biologicals), anti-runt-related transcription factor 2 (anti-Runx2; monoclonal; 1:1000; ab264077; Abcam), anti-SMAD3/2/7/9 (monoclonal; 1:1000; 5678S; Cell Signaling Technology, Danvers, MA, USA), anti-phospho (p)-SMAD2/3/5 (monoclonal; 1:1000; 8828S; Cell Signaling Technology), anti-SMAD1/5/9 (monoclonal; 1:500; AF6014; Affinity Biologicals), anti-phospho-SMAD1/5/9 (polyclonal; 1:1000; AF8313; Affinity Biologicals), and anti-β-actin (monoclonal; 1:5000; ab8226; Abcam). Horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5000; BA1055; Boster, Wuhan, China) was used as the secondary antibody. A chemiluminescence imaging system (Chemilume 6200T, Clinx Science Instruments, Shanghai, China) was used for detection.

**Experimental protocols and surgical procedures**
A total of 63 Sprague-Dawley rats were divided into three groups of 21: (1) control: animals that underwent surgery for partial resection of the patellar tendon; (2) GelMA: animals that underwent surgery for patellar tendon partial resection and were inoculated with 30 μL GelMA (EFL-GM-60, 10% w/v) over the tendon defect; and (3) ADSC-Exos: animals for which the injured patellar tendon was treated with 30 μL GelMA containing 200 μg of ADSC-Exos. The exosome content was determined according to previous studies [19]. Rats were anesthetized with 0.3% sodium pentobarbital (30 mg/kg). The right patellar tendon was surgically exposed, and the central 1/3 of the tendon tissue was removed as in previous studies [21]. GelMA was then inoculated into the lesion and cross-linked into a gel state by ultraviolet light. The skin incision was closed using 4-0 sutures. The modeling process is shown in Figure S1. Animals from each group (n = 6) were euthanized on day 7 for immunofluorescence analyses and on days 14 or 28 for immunohistochemical analysis.
Histopathological and immunohistochemical analyses
Paraffin-embedded tendon tissues were sectioned at a thickness of 4 μm. The tissues were then stained with H&E for histopathological analysis. The stained patellar tendons were evaluated according to a previously described parallel fiber alignment scoring method using light microscopy [22]. The scoring scale was as follows: 0, 0–25% parallel fiber alignment; 1, 25–50% parallel fiber alignment; 2, 50–75% parallel fiber alignment; and 3, 75–100% parallel fiber alignment.

For immunohistochemical analyses, the paraffin sections of tendon tissues were incubated with Immuno-Block reagent for 30 min after being deparaffinized and rehydrated. The sections were then incubated with the rabbit primary antibodies: anti-CD146 (monoclonal; 1:250; ab75769; Abcam), anti-TNMD (polyclonal; 1:100; ab203676; Abcam), anti-collagen I (polyclonal; 1:100; ab270993; Abcam), anti-SCXA (polyclonal; 1:100; DF13293; Affinity), anti-ALP (polyclonal; 1:200; DF6225; Affinity), and anti-Runx2 (monoclonal; 1:1000; ab264077; Abcam). Horseradish peroxidase-conjugated goat anti-rabbit IgG (1:500; 115-035-003; Jackson ImmunoResearch, Ely, UK) was used as the secondary antibody. After counterstaining with hematoxylin, the sections were dehydrated and fixed. The area of the positive signal was determined using the Imagej software.

For immunofluorescence analyses, the sections of tendon tissues were incubated with the rabbit primary antibodies: anti-CCR7 (monoclonal; 1:200; ab32527; Abcam), anti-CD163 (monoclonal; 1:100; ab182422; Abcam), anti-IL-6 (monoclonal; 1:100; TA500067S; OriGene), and anti-IL-10 (monoclonal; 1:100; ab33471; Abcam). The sections were then incubated with secondary antibodies (1:200; SA00013; Proteintech, Rosemount, IL, USA) for 1 h. The nuclei were labeled with 4′,6-diamidino-2-phenylindole, and photos were taken with a DM4 B microscope (Leica). Three fields per section were selected randomly for statistical analysis. Positive signals were quantified with the Imagej software.

Biomechanical testing
At week 4, patellar tendon tissues from each group \((n = 3)\) were taken, and two bony ends of a healing tendon were fixed on a universal material testing machine (Zwick, Roell, Germany). The tissues were investigated using a standard failure test with a testing speed of 5 mm/min. Failure load (N) and stiffness (N/mm) were obtained by the software of the testing machine. Young’s modulus \((\text{N} \times 10^3/\text{mm}^2)\) was calculated after measuring the cross-sectional area (mm²) of the tendon with a vernier caliper.

Statistical analyses
All values are expressed as means ± standard deviation. Quantitative data for each group were analyzed by a one-way analysis of variance followed by the Tukey-Kramer test. \(P < 0.05\) was considered statistically significant.

Results
Characterization of ADSCs
ADSCs exhibited long fusiform morphology (Figure S2A) and differentiated into adipocytes, osteoblasts, and chondroblasts in vitro (Figure S2B). Flow cytometric analysis of ADSC surface markers revealed that the cells were CD90- and CD105-positive, and CD34-, CD45-, and CD11b-negative (Figure S2C).

Characterization and internalization of ADSC-Exos
TEM revealed that ADSC-Exos were round or elliptical vesicular structures (Fig. 1a). The NTA revealed the mean diameter of ADSC-Exos to be 109.6 nm (Fig. 1b). Western blot analyses confirmed that the ADSC-Exo surface markers CD9, TSG101, and HSP70 were positively expressed (Fig. 1c). In addition, ADSC-Exos were internalized by TSCs and showed red fluorescence (Fig. 1d). Finally, the release behavior of ADSC-Exos loaded in GelMA is shown in Fig. 1e.

ADSC-Exos promoted the proliferation, migration, and tenogenic differentiation of TSCs
We first measured the effect of the different concentrations of ADSC-Exos on the proliferation and migration of TSCs. The EdU assay showed that ADSC-Exos promoted TSC proliferation (Fig. 2a, B). Further, the transwell assay confirmed that ADSC-Exos promoted TSC migration with increasing concentrations of exosomes (Fig. 2c, d). The scratch test showed results consistent with these findings (Fig. 2e, f). Then, we investigated whether ADSC-Exos affected the differentiation of TSCs. Western blot analyses showed ADSC-Exos significantly increased the protein expression of TNMD, collagen I, and SCXA but had no effect on ALP or Runx2 (Fig. 2g–l). These results suggest that ADSC-Exos promote the tenogenic differentiation ability of TSCs but have no effect on osteogenic differentiation.

ADSC-Exos activated the SMAD2/3 and SMAD1/5/9 pathways
The SMAD signaling pathways play vital roles in regulating stem cell activity. SMAD2/3 and SMAD1/5/9 are two typical SMAD signaling pathways. Therefore, we examined the changes in these two pathways after ADSC-Exo uptake by TSCs. Western blot analyses showed that ADSC-Exos increased the p-SMAD2/3 and p-SMAD1/5/9 expression in TSCs (Fig. 3a–c), suggesting that the uptake of ADSC-Exos by TSCs activated the SMAD2/3 and SMAD1/5/9 signaling pathways. Furthermore, we pretreated TSCs with the SMAD2/3 inhibitor, SB431542,
or the SMAD1/5/9 inhibitor, dorsomorphin, for 30 min. Western blot analyses showed that SB431542 and dorsomorphin inhibited the phosphorylation of SMAD2/3 and SMAD1/5/9, respectively (Fig. 3d–f).

**ADSC-Exos regulated TSC proliferation, migration, and tenogenic differentiation by activating SMAD2/3 and SMAD1/5/9 signaling pathways**

To investigate the regulatory effect of ADSC-Exos, we evaluated their effects on the proliferation, migration, and tendon differentiation of TSCs by pretreating them with SB431542 or dorsomorphin. As expected, the proliferation (Fig. 3g, h) and migration (Fig. 3i–l) of TSCs were significantly decreased in the ADSC-Exos + SB431542 and ADSC-Exos + dorsomorphin groups compared with that in the ADSC-Exos only group. Similarly, western blot analyses showed that pretreatment with SB431542 or dorsomorphin significantly decreased the expression of the tenogenic differentiation genes, TNMD, collagen I, and SCXA, in TSCs (Fig. 3m–p).

**ADSC-Exos regulated the early inflammatory response during tendon healing**

We investigated the in vivo effect of ADSC-Exos on early healing of tendon injury. At week 1 after injury, the level of CCR7 (M1 macrophage marker) decreased in the ADSC-Exo group while the level of CD163 (M2 macrophage marker) increased (Fig. 4a, b). Furthermore, IL-10 (an anti-inflammatory factor) increased, and IL-6 (a pro-inflammatory factor) decreased (Fig. 4c, d). Quantitative analyses showed there were more CD163⁺ and IL-10⁺ cells in the ADSC-Exo group, while CCR7⁺ and IL-6⁺ cells predominated in the control and GelMA groups (Fig. 4e).

**ADSC-Exos improved the healing of tendon injury**

We next assessed whether ADSC-Exos contributed to the healing of patellar tendon injury in rats. H&E staining showed the ADSC-Exo group had much more regular alignment of the fibrous tissue in the defect area at week 2 compared with the other groups (Fig. 5a, o). At week 4, the collagen fiber alignment in the ADSC-Exo group was more compact than in the other groups (Fig. 5h).

Immunohistochemical analyses showed higher expression of TNMD, collagen I, and SCXA in the ADSC-Exo group at week 2 than in the control and GelMA groups (Fig. 5b–d). At week 4, the expression of these three genes remained high in the ADSC-Exo group (Fig. 5i–k). Furthermore, ALP and Runx2 expression were unchanged among the three groups at both weeks 2 and 4 (Fig. 5e, f, l, m). The results of the quantitative analyses are shown in Fig. 5g, n.

Biomechanical testing showed that the failure load, stiffness, and Young’s modulus of the patellar tendon in
Fig. 2 ADSC-Exos promote the proliferation, migration, and tenogenic differentiation of TSCs. 

a. b. Effect of different concentrations of ADSC-Exos on the proliferation of TSCs by EdU assays.

c–f. Effect of different concentrations of ADSC-Exos on the migration of TSCs by transwell assays and scratch assays.

g–l. Western blot analysis of protein levels of TNMD, collagen I, SCXA, ALP, and Runx2 induced by different concentrations of ADSC-Exos. Bars, 100 μm. Data are represented as mean ± SD. * vs control group; # vs 25 group; & vs 50 group; n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, #P < 0.05, ##P < 0.001, ###P < 0.0001.
Fig. 3 (See legend on next page.)
ADSC-Exos promote the proliferation, migration, and tenogenic differentiation of TSCs via the SMAD2/3 and SMAD1/5/9 signaling pathways. a–c Western blot analysis of protein levels of p-SMAD2/3 and p-SMAD1/5/9 induced by different concentrations of ADSC-Exos. d–f SB431542 and dorsomorphin inhibit the activation of SMAD2/3 and SMAD1/5/9 induced by ADSC-Exos, respectively. g, h EdU assay showed that ADSC-Exos-mediated TSC proliferation was suppressed by inhibitors SB431542 and dorsomorphin. i–l Transwell assay and scratch assays showed that ADSC-Exos-mediated TSC migration was suppressed by inhibitors SB431542 and dorsomorphin. m–p Western blot analysis of protein levels of TNMD, collagen I, and SCXA promoted by ADSC-Exos was inhibited by inhibitors SB431542 and dorsomorphin. Bars, 100 μm. Data are represented as mean ± SD. *vs control group; †vs ADSC-Exos group; n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, †P < 0.05, ††P < 0.01, †††P < 0.001, ††††P < 0.0001.

Fig. 4 ADSC-Exos inhibits inflammatory expression in tendon injury. a–d The expression of CCR7+, CD163+, IL-6+, and IL-10+ cells were detected by immunofluorescence at week 1. e Positive ratio of inflammation-related factors (n = 6). Bars, 50 μm. Data are represented as mean ± SD. *vs control group; †vs GelMA group. **P < 0.01, ***P < 0.001, ****P < 0.0001, #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001.
Fig. 5 (See legend on next page.)
the ADSC-Exo group were significantly increased compared with the control and GelMA groups (Fig. 5p-s).

**ADSC-Exos promoted TSC proliferation during tendon healing**

To investigate the mechanism by which ADSC-Exos promoted tendon healing in vivo, we measured the number of TSCs in the tendon tissue during early healing. CD146 was used as a marker of TSCs [23]. Immunohistochemical staining showed that the number of CD146+ TSCs in the injured tendon increased with extension of the healing time. Meanwhile, as expected, the number of CD146+ TSCs increased significantly in the ADSC-Exo group (Fig. 6a, b).

**Discussion**

Improving the quality of healing after tendon injury remains a major medical challenge. TSCs play an important role in tendon healing [24]. However, Zhang et al. reported that culture-expanded TSCs were prone to lose their phenotypic characteristics and exhibited reduced regeneration ability [25]. Therefore, activating the proliferation and differentiation of TSCs is key to improving tendon healing.

We first studied the influence of ADSC-Exos on TSCs in vitro. The results revealed that ADSC-Exos were internalized into TSCs and promoted their proliferation, migration, and tenogenic differentiation. Implantation of TSCs improves tendon healing in rats [26–29], and the activity of TSCs determines the quality of this healing. It
is well-known that the SMAD family of the signaling pathways plays important roles in regulating stem cell functions, with two typical SMAD signaling pathways, SMAD2/3 and SMAD1/5/9, having potential significance in regulating the activity of TSCs [30–32]. Accordingly, we hypothesized that ADSC-Exos promoted the proliferation, migration, and tenogenic differentiation of TSCs by activating the SMAD family signaling pathways. As expected, ADSC-Exos increased the phosphorylation of SMAD2/3 and SMAD1/5/9 in TSCs, which was later found to be attenuated by the inhibitors, SB431542 and dorsomorphin, respectively. We also found that the application of these two inhibitors blocked the effects of ADSC-Exos on the activity of TSCs. These results support the hypothesis that ADSC-Exos enhanced the proliferation and migration of TSCs by promoting the activation of the SMAD2/3 and SMAD1/5/9 signaling pathways.

Tenogenic differentiation is a complex process. SCXA is a key molecule in the early development of tendons. It is responsible for the differentiation of TSCs into tenocytes and the positive regulation of TNMD expression [33, 34]. Subsequently, the TNMD gene is necessary for tendon maturation and has a positive effect on the self-renewal of TSCs [35]. In addition, the expression of collagen I determines the strength of tendons [36]. Because abnormal ossification during tendon healing affects normal tendon functions, we hypothesized that ADSC-Exos would be able to promote tenogenic differentiation and inhibit osteogenic differentiation of TSCs. The results showed that, indeed, ADSC-Exos increased TNMD, collagen I, and SCXA expression in TSCs via activation of the SMAD2/3 and SMAD1/5/9 pathways. However, ADSC-Exos did not affect the expression of ALP or Runx2 in TSCs. This suggests that ADSC-Exos could effectively promote tenogenic differentiation of TSCs, but not inhibit osteogenic differentiation.

Scar formation caused by inflammation after tendon injury is a major cause of histological changes affecting tendon healing prognosis [37]. Therefore, inhibiting the early inflammatory response of tendon injury is beneficial to early healing. Recent studies reported that MSCs can elicit immunoregulatory responses by modulating the pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophage polarization, inducing regulatory T cells, and producing anti-inflammatory cytokines [38, 39]. Considering exosomes are the main substances used by MSCs to exert their effectiveness, we hypothesized that exosomes would recapitulate the immunomodulatory effects of their parent cells. In the current study, we found that CD163+ M2 macrophages were increased significantly in the ADSC-Exo group. In addition, the M2-stimulating factor, IL-10, was increased in the ADSC-Exo group. Furthermore, Shen et al. found that ADSC-Exos reduced the early inflammatory response after tendon injury by regulating macrophages, whereas some studies have confirmed that ADSC-Exos were able to modulate macrophages from an M1 to M2 phenotype in vitro [10, 40–43]. Therefore, we suggest that ADSC-Exos can alleviate early inflammation after tendon injury by modulating macrophages.

Tissue integrity is the standard for evaluating the quality of tendon healing. We used the central 1/3 patellar tendon injury rat model to evaluate tendon healing. H&E staining showed that collagen fibers in the ADSC-Exo group were more regular compared to those in the control and GelMA groups. In addition, the biomechanical properties of the tendon tissues in the ADSC-Exo group were significantly improved at 4 weeks. We also investigated the regulatory effect of ADSC-Exos on TSCs in vivo. Immunohistochemical analyses showed that ADSC-Exos promoted the expression of tenogenic differentiation genes in vivo but did not inhibit the expression of osteogenic differentiation genes in the injured area.

In previous reports, CD146 has been used as a surface marker of TSCs; CD146+ TSCs switch to an activated state during tendon-injury healing and increase their proliferation, migration, and tenogenic differentiation ability [44]. Our results showed that the expression of CD146+ TSCs in the ADSC-Exo group was the highest among the three groups. This indicated that ADSC-Exos promoted the proliferation ability of CD146+ TSCs.

Exosomes are generally used to repair tissues by intravenous or local injection. However, due to difficulty in their local retention, exosomes are unable to exert their full biological efficacy. GelMA is a photosensitive biopolymer with excellent biocompatibility and degradability and is widely used in various tissue engineering applications [45, 46]. GelMA exists in a liquid state at 37°C and becomes cross-linked under ultraviolet light to form a gel state with ECM properties. Because of its mild response to environmental conditions, GelMA has great advantages for use in biomedicine and is expected to be applicable for various clinical treatments [47]. For instance, Aubin et al. attempted to change the proliferative arrangement of different cells using micropatterned GelMA to provide a theoretical basis for constructing functional tissues in vitro [48]. Zou et al. used GelMA to construct biomimetic bone with a trabecular bone structure, and Hu et al. used GelMA microspheres loaded with small extracellular vesicles to promote cartilage regeneration [20, 49]. In the current study, GelMA was used as a carrier of ADSC-Exos to provide a good microenvironment for exosome storage and their gradual absorption. The ADSC-Exo-loaded GelMA attached to the defect of the patellar tendon in a gel-like manner.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13287-021-02410-w.

Acknowledgements

We would like to acknowledge the reviewers for their helpful comments on this paper.

Authors’ contributions

HCL and MZZ contributed to the cytology experiment, animal experiments, data acquisition, data analysis, and manuscript writing. MYS, TTZ, WJL, and HCL and MZZ provided experimental technical support and final approval of the manuscript. QBC and ZZL took part in the experimental design, text revision, and final approval of the manuscript. The authors read and approved the final manuscript.

Additional file 1: Figure S1. Patellar tendon injury model. A Exposure and removal of central 1/3 right patellar tendon tissue. B ADSC-Exos loaded GelMA injected into the location of the patellar tendon defect. C Radiation GelMA with 405nm light source for 30s. D Photocross-linking under radiation forms a gel state.

Additional file 2: Figure S2. Characterization of ADSCs. A Morphology of ADSCs. B Adipogenic, osteogenic and chondrogenic differentiation of ADSCs. C Flow cytometry for detection of ADSC surface markers. Bars, 100μm.

Conclusions

Overall, our results showed that ADSC-Exos were absorbed by TSCs and promoted their proliferation, migration, and tenogenic differentiation via the SMAD2/3 and SMAD1/5/9 signaling pathways. In addition, ADSC-Exos alleviated early inflammation and promoted tendon healing. These findings suggest the potential clinical value of ADSC-Exos in treating tendon defects and provide a new approach for the treatment of tendon injuries.

Abbreviations

ADSCs: Adipose-derived mesenchymal stromal cells; ADSC-Exos: Adipose-derived mesenchymal stromal cell-derived exosomes; TSCs: Tendon stem cells; ECM: Extracellular matrix; DMEM: Dulbecco’s modified Eagle’s medium; FBS: Fetal bovine serum; NTA: Nanoparticle tracking analysis; TEM: Transmission electron microscopy; EdU: 5-Ethynyl-2′-deoxyuridine; H&E: Hematoxylin-eosin; TNMD: Tenomodulin; SCXA: Scleraxis; ALP: Alkaline phosphatase; Runx2: Runt-related transcription factor 2; GelMA: Gelatin methacryloyl

References

1. Lomas AJ, Ryan CN, Sonuhanova A, et al. The past, present and future in scaffold-based tendon treatments. Adv Drug Deliv Rev. 2015;84:257–77. https://doi.org/10.1016/j.addr.2014.11.022.
2. Docheva D, Müller SA, Majewski M, Evans CH. Biologics for tendon repair. Adv Drug Deliv Rev. 2015;84:222–39. https://doi.org/10.1016/j.addr.2014.11.015.
3. Nichols AEC, Best KT, Loiselle AE. The cellular basis of fibrotic tendon healing: challenges and opportunities. Transfus Sci. 2019;105:156–68. https://doi.org/10.1111/trs.13902.
4. Rui YF, Liu PP, Li G, et al. Isolation and characterization of multipotent rat tendon-derived stem cells. Tissue Eng Part A. 2010;16(5):1549–58. https://doi.org/10.1089/teng.2009.0529.
5. Manning CN, Haviroglu N, Knutsen E, Sakiyama-Elbert SE, Silva MJ, Thomopoulos S, et al. The early inflammatory response after flexor tendon healing: a gene expression and histological analysis. J Orthop Res. 2014;32(5):645–52. https://doi.org/10.1002/jor.22575.
6. Dormann S, Stewart M. Cellular and molecular factors influencing tendon repair. Tissue Eng Part B Rev. 2017;23(4):307–17. https://doi.org/10.1089/teng.2016.0445.
7. Howell K, Chen C, Bell R, Laudier D, Tufa SF, Keene DR, et al. Novel model of tendon regeneration reveals distinct cell mechanisms underlying regenerative and fibrotic tendon healing. Sci Rep. 2017;7(1):45238. https://doi.org/10.1038/srep45238.
8. Qiu G, Zheng G, Ge M, Wang J, Huang R, Shu Q, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018;9(1):320. https://doi.org/10.1186/s13287-018-1069-9.
9. Torres-Torrillas M, Rubio M, Damia E, Cuervo B, del Romero A, Peláez P, et al. Adipose-derived mesenchymal stem cells: a promising tool in the treatment of musculoskeletal diseases. Int J Mol Sci. 2019;20(12):3105. https://doi.org/10.3390/ijms20123105.
10. Shen H, Yoneda S, Abu-Amer Y, Guilak F, Gelberman RH. Stem cell-derived extracellular vesicles attenuate the early inflammatory response after tendon injury and repair. J Orthop Res. 2020;38(1):117–27. https://doi.org/10.1002/jor.24406.
11. Cui X, He Z, Liang Z, Chen Z, Wang H, Zhang J. Exosomes from adipose-derived mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through Wnt/β-catenin signaling pathway. J Cardiovasc...
28. Yang Z, Cao H, Gao S, Yang M, Lyu J, Tang K. Effect of tendon stem cells in vitro. Biotechnol Lett. 2017;39(5):711-9. https://doi.org/10.1007/s10529-017-2296-3.

29. Veronesi F, Samalansa F, Tichoni M, Maglio M, Nicoli Aldini N, Fini M. Mesenchymal stem cells for tendon healing: what is on the horizon? J Tissue Eng Regen Med. 2017;11(13):202-19. https://doi.org/10.1002/term.2209.

30. Shukunami C, Takimoto A, Oro M, Hiraki Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev Biol. 2006;298(1):234-47. https://doi.org/10.1016/j.ydbio.2006.06.036.

31. Alberton P, Dev S, Popov C, Shukunami C, Schieker M, Docheva D. Loss of tenomodulin results in reduced self-renewal and augmented senescence of tendon stem/progenitor cells. Stem Cells Dev. 2015;24(5):597-609. https://doi.org/10.1089/scd.2014.0314.

32. Heineimer ME, Kjaer M. In vivo investigation of tendon responses to mechanical loading. J Musculoskelet Neuronal Interact. 2011;11(2):115-23.

33. Thakani FG, Roesch ZK, Dilliso MF, Radwan MW, Kovilam A, Gross RM et al. Association of inflammatory responses and ECM disorganization with HMGB1 upregulation and NLRP1 inflammasome activation in the injured rotator cuff tendon. Sci Rep. 2018;8(1):9818. https://doi.org/10.1038/s41598-018-27250-2.

34. Shukunami C, Takimoto A, Oro M, Hiraki Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev Biol. 2017;312(1):234-47. https://doi.org/10.1016/j.ydbio.2006.06.036.

35. Alberton P, Dev S, Popov C, Shukunami C, Schieker M, Docheva D. Loss of tenomodulin results in reduced self-renewal and augmented senescence of tendon stem/progenitor cells. Stem Cells Dev. 2015;24(5):597-609. https://doi.org/10.1089/scd.2014.0314.

36. Veronesi F, Samalansa F, Tichoni M, Maglio M, Nicoli Aldini N, Fini M. Mesenchymal stem cells for tendon healing: what is on the horizon? J Tissue Eng Regen Med. 2017;11(13):202-19. https://doi.org/10.1002/term.2209.

37. Shukunami C, Takimoto A, Oro M, Hiraki Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev Biol. 2017;312(1):234-47. https://doi.org/10.1016/j.ydbio.2006.06.036.

38. Shukunami C, Takimoto A, Oro M, Hiraki Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev Biol. 2017;312(1):234-47. https://doi.org/10.1016/j.ydbio.2006.06.036.